Therapeutic Asset Ratings

1,028 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
rc48-adc Ovarian Neoplasm	Seagen, a wholly owned subsidiary of Pfizer	P2	CCC (51)
rc48-adc Prostate Adenocarcinoma	SOLTI Breast Cancer Research Group	P2	CCC (51)
rc88 Fallopian Tube Cancer	RemeGen Co., Ltd.	P2	CCC (51)
Sacituzumab Tirumotecan Neoadjuvant Therapy	Yantai Yuhuangding Hospital	P2	CCC (51)
Shr-A2009 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (51)
T-Dxd Radiotherapy	Fudan University	P2	CCC (51)
Tisotumab Vedotin Colorectal Neoplasm	Seagen, a wholly owned subsidiary of Pfizer	P2	CCC (51)
Trastuzumab Deruxtecan Colorectal Adenocarcinoma	Gruppo Oncologico del Nord-Ovest	P2	CCC (51)
Trastuzumab Deruxtecan Lymphoma, Non-Hodgkin	American Society of Clinical Oncology	P2	CCC (51)
Trastuzumab Deruxtecan Metastatic Neoplasm	UNICANCER	P2	CCC (51)
Trastuzumab Deruxtecan Rectum Adenocarcinoma	Gruppo Oncologico del Nord-Ovest	P2	CCC (51)
Trastuzumab Emtansine Colorectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Trastuzumab Emtansine Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Trastuzumab Imbotolimod HER2 Positive Breast Carcinoma	Bolt Biotherapeutics, Inc.	P2	CCC (51)
Trastuzumab Imbotolimod Breast Cancer	Bolt Biotherapeutics, Inc.	P2	CCC (51)
Trastuzumab Rezetecan Breast Cancer	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P2	CCC (51)
rc48-adc Metastatic Cancer	BeOne Medicines	P1/2	CCC (51)
Ifinatamab Deruxtecan Prostate Cancer	Merck Sharp & Dohme LLC	P3	CCC (50)
Investigational Drug: Recombinant Anti-Her2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates For Breast Cancer	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	P3	CCC (50)
Datopotamab Deruxtecan Colorectal Cancer	AstraZeneca	P2	CCC (50)
Datopotamab Deruxtecan Ovarian Cancer	AstraZeneca	P2	CCC (50)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Advanced Solid Tumor	Astellas Pharma Global Development, Inc.	P2	CCC (50)
Immunoglobulin G1 [240-alanine,241-alanine], anti-(human folate receptor ?) (human monoclonal PRO1184 ?1-chain, complex with human monoclonal PRO1184 ?-chain, dimer, 214??,214???,226,226?,232,232?,235,235?-octakis(thioether) with N6-[39-[bis(1-deoxy-D-glucitol-1-yl)amino]-1-oxo-4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxanonatriacont-1-yl]-N2-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-L-lysyl-L-valyl-N5-(aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]carbonyl]oxy]methyl]phenyl]-L-ornithinamide Non-Small Cell Lung Carcinoma	Genmab	P2	CCC (50)
Ladiratuzumab Vedotin Breast Cancer	Hoffmann-La Roche	P2	CCC (50)
Loncastuximab Tesirine Large B-Cell Lymphoma	University of Miami	P2	CCC (50)

Showing 576 to 600 of 1,028 assets

PreviousPage 24 of 42Next